Needham & Company LLC Reiterates Buy Rating for OrthoPediatrics (NASDAQ:KIDS)

OrthoPediatrics (NASDAQ:KIDS)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $42.00 target price on the stock. Needham & Company LLC’s price target points to a potential upside of 96.35% from the company’s current price.

KIDS has been the topic of a number of other reports. Lake Street Capital began coverage on shares of OrthoPediatrics in a research note on Monday. They set a “buy” rating and a $37.00 price target on the stock. Truist Financial cut their price target on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus reduced their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, OrthoPediatrics has an average rating of “Moderate Buy” and a consensus target price of $37.20.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS opened at $21.39 on Wednesday. OrthoPediatrics has a 12 month low of $20.78 and a 12 month high of $35.99. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The stock has a market cap of $519.50 million, a price-to-earnings ratio of -17.39 and a beta of 1.17. The company has a 50 day simple moving average of $24.20 and a two-hundred day simple moving average of $24.76.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same period last year, the firm earned ($0.23) EPS. As a group, analysts predict that OrthoPediatrics will post -0.93 earnings per share for the current year.

Insider Activity

In other news, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $133,224.74. Following the sale, the insider now directly owns 148,788 shares of the company’s stock, valued at approximately $3,698,869.68. The trade was a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now owns 110,767 shares of the company’s stock, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock valued at $589,978 over the last quarter. Company insiders own 31.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KIDS. Wellington Management Group LLP boosted its position in OrthoPediatrics by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 883,221 shares of the company’s stock worth $23,944,000 after acquiring an additional 122,846 shares during the period. Barclays PLC lifted its holdings in shares of OrthoPediatrics by 319.3% during the third quarter. Barclays PLC now owns 25,298 shares of the company’s stock valued at $686,000 after purchasing an additional 19,264 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of OrthoPediatrics by 2.1% in the third quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock worth $10,615,000 after buying an additional 7,972 shares during the period. BNP Paribas Financial Markets boosted its stake in OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after purchasing an additional 1,929 shares during the period. Finally, Centiva Capital LP purchased a new position in shares of OrthoPediatrics during the third quarter valued at $319,000. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.